EU Regulator Probing Link Between Weight-Loss Drugs And Suicide

The European Union’s drug regulator is probing a possible link between diabetes drugs, popular for weight loss, and suicidal thoughts.
The European Medicines Agency (EMA) is assessing 150 reports of possible cases of self-injury among people taking a class of medications called GLP-1 agonists, which play a role in regulating metabolism and hunger.
The EMA said the Icelandic Medicines Agency initiated the review due to reports of suicidal thoughts and self-injury in individuals using liraglutide and semaglutide drugs for weight loss.

15 thoughts on “EU Regulator Probing Link Between Weight-Loss Drugs And Suicide

Leave a Reply

Your email address will not be published. Required fields are marked *